002880 Shen Zhen Weiguang Biological Products
- 29.57
- +0.26+0.89%
Shen Zhen Weiguang Biological Products News
Express News | Weiguang Biotech: Received the “Drug Registration Certificate” for human prothrombin complex
Weiguang Biology (002880.SZ): The main business is blood products. It is a bioactive preparation prepared from healthy human plasma using biological processes or separation and purification technology
Gelonghui, May 24 | Weiguang Biology (002880.SZ) said on the investor interactive platform that the company's main business is blood products, which are bioactive preparations prepared using biological processes or separation and purification techniques using healthy human plasma as raw materials. Weiguang Life Science Park focuses on synthetic biology, brain science, etc., to build a core technology platform for genes, macromolecules, and cells, and is committed to building a biomedical specialty park characterized by innovation incubation and transformation of results.
Weiguang Biotech (002880): Performance is in line with expectations, fiber revenue is growing rapidly
Incident: The company released the 2023 report & 2024 quarterly report. In 2023, it achieved revenue of 1.05 billion yuan, +57% year-on-year, and realized net profit of 220 million yuan to mother, +86.1% year-on-year, after deducting net profit of 210 million yuan other than the mother
Weiguang Biotech (002880.SZ): Net profit of 468.319 million yuan in the first quarter increased 2.40% year-on-year
Gelonghui, April 25 | Weiguang Biotech (002880.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 226 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 468.319 million yuan, up 2.40% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 455.227 million yuan, up 1.23% year on year; basic earnings per share were 0.2065 yuan.
Weiguang Biotech (002880.SZ) plans to launch the third phase of the employee stock ownership plan
Weiguang Biotech (002880.SZ) released the third phase of the employee stock ownership plan (draft). The employee stock ownership plan raised funds...
Weiguang Biology (002880.SZ): Pulping work was carried out smoothly in 2023, with an annual slurry harvesting volume of about 517 tons
Gelonghui, January 22丨An investor asked Weiguang Biotech (002880.SZ) on the investor interactive platform, “How much is the company's pulp collection volume in 2023, and if Sinopharm enters the market, whether the company will divest the blood products business and avoid competition with Tiantan Biotech”. The company replied that the company's pulping work in 2023 was carried out smoothly, with an annual pulp collection volume of about 517 tons. Please pay attention to the company's announcement for details on changes in the shareholding of the company's controlling shareholder.
Weiguang Biotech (002880.SZ): 2023 net profit pre-increased 69%-111%
Gelonghui, January 19 | Weiguang Biotech (002880.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 199 million yuan to 248 million yuan, an increase of 69%-111% over the same period of the previous year; net profit after deducting non-recurring profit and loss was 171 million yuan to 213 million yuan, an increase of 69%-111% over the same period last year; basic earnings per share were 0.88 yuan/share - 1.10 yuan/share. During the reporting period, the overall demand for blood products was good, the company had sufficient orders for related blood products, and actual operating income and net profit
Weiguang Biotech (002880.SZ): Currently no gene editing therapy is being developed
On December 28, Gelonghui Biotech (002880.SZ) said on the investor interactive platform that the company is currently not developing gene editing therapy.
Weiguang Biotech (002880.SZ)'s approval for non-public stock issuance expires
Weiguang Biotech (002880.SZ) issued an announcement. The company received an announcement from the China Securities Regulatory Commission in November 2022...
Everbright Securities: The expansion of both supply and demand in the blood products industry is expected to usher in a golden period of development
As the supply capacity of raw plasma continues to increase, product sales in the blood products industry are expected to benefit from increased demand and ushered in a golden period of development.
Weiguang Biological Products Gets Registration Certificate for Human Coagulation Factor VIII Drug
Shenzhen Weiguang Biological Products (SHE:002880) obtained a drug registration certificate from China's National Medical Products Administration for its drug, human coagulation factor VIII. The drug,
Weiguang Biotech (002880.SZ) obtained a drug registration certificate relating to human coagulation factor VIII
Weiguang Biotech (002880.SZ) issued an announcement. The company has recently been approved and issued by the State Drug Administration...
[BT Financial Report Instantaneous Analysis] Weiguang Biotech's 2023 Quarterly Report: Operating income increased by 78.75%, net profit increased by 107.83%, and net operating cash flow increased dramatically
This financial report was announced at 18:12:51 2023-10-25 at 18:12:51. Shenzhen Weiguang Biological Products Co., Ltd. (stock code: 002880) is one of the earliest domestic enterprises engaged in the production and operation of blood products, and one of the first to pass the national GMP certification. The company's main products include human albumin, immunoglobulins, and coagulation factors, etc., with a total of 21 specifications. The company has reached cooperation agreements with Belarusian government agencies on production licenses and technology transfer services for human blood albumin and intravenous human immunoglobulin (pH4), becoming the first in China to achieve blood product technology
Weiguang Biotech (002880): Revenue growth was in line with expectations, and R&D investment increased in the third quarter
Event: The company released its three-quarter report for 2023. The company achieved revenue of 740 million yuan, +78.8% year-on-year, net profit of 150 million yuan, +107.8% year-on-year, and net profit of 150 million yuan after deducting non-return net profit of 150 million yuan, +1 year on year
Weiguang Biotech (002880.SZ) released results for the first three quarters, with net profit of 151 million yuan, an increase of 107.83% over the previous year
Weiguang Biotech (002880.SZ) released its report for the first three quarters of 2023, with revenue of 735 million yuan, the same...
Weiguang Biotech (002880.SZ) distributes 2 yuan per 10 shares for the semi-annual share registration date is October 30
Weiguang Biotech (002880.SZ) announced that the company will implement the distribution of benefits for the semi-annual period of 2023, every 10...
Weiguang Biotech (002880.SZ): Currently, there is no research and development of diet drugs
Glonghui, Oct. 9丨An investor asked Weiguang Biotech (002880.SZ) on the investor interactive platform, “Does the company develop consumer-type products, such as diet pills?” The company replied that it has not yet carried out research and development of diet pills.
Weiguang Biology (002880.SZ): The freeze-dried human rabies vaccine (chicken germ cells) project communicated and exchanged opinions in accordance with IND, and related supplementary research work is still being carried out
Gelonghui, October 9 | An investor asked Weiguang Biotech (002880.SZ) on the investor interactive platform, “How far has your company's freeze-dried rabies vaccine (chicken germ cells) progressed to? How are other R&D projects progressing?” The company replied that the freeze-dried human rabies vaccine (chicken germ cells) project communicated and exchanged opinions in accordance with IND, and related supplementary research work is still being carried out.
Weiguang Biology (002880): Pioneer of differentiated blood products, the entry of Sinopharm is expected to empower
Weiguang Biotech is a leading blood products company in China. In terms of scale, the company is actively preparing intelligent engineering construction projects, while also exploring the potential of existing pulp stations and strengthening the expansion of new pulp stations to maintain a steady increase in pulp collection volume; in terms of products, the company is steadily advancing its research pipeline
Weiguang Biotech (002880): Product revenue has increased dramatically, and annual results can be expected
Event: The company released its semi-annual report for 2023: the first half of 2023 achieved revenue of 460 million yuan, +97.2% year-on-year, and net profit of 100 million yuan, +115.5% year-on-year, minus non-net profit of 99.48 million yuan, the same
Analysis
Price Target
No Data
